| |
Oestrogen-only users No. of GORD cases OR (95% CI) P
|
Tibolone users No. of GORD cases OR (95% CI) P
|
Combined HRT users No. of GORD cases OR (95% CI) P
|
Progestogen users No. of GORD cases OR (95% CI) P
|
|---|
|
GORD
|
|
Hormone
|
144
|
21
|
137
|
56
|
|
Non-hormone
|
572
|
572
|
572
|
572
|
|
OR (95% CI) p
|
1.49 (1.18–1.89) 0.001
|
0.79 (0.45–1.4) 0.419
|
1.09 (0.87–1.37) 0.445
|
1.29 (0.90–1.84) 0.170
|
|
NSAIDs <30d
|
|
Hormone
|
23
|
3
|
22
|
12
|
|
Non-hormone
|
99
|
99
|
99
|
99
|
|
OR (95% CI) p
|
1.52 (1.09–2.12) 0.014
|
1.08 (0.48–2.48) 0.848
|
1.25 (0.92–1.71) 0.150
|
1.09 (0.68–1.74) 0.718
|
|
NSAIDs ≥30d
|
|
Hormone
|
75
|
14
|
62
|
21
|
|
Non-hormone
|
233
|
233
|
233
|
233
|
|
OR (95% CI) p
|
2.06 (1.59–2.66) < 0.001
|
3.42 (1.22–9.64) 0.020
|
1.97 (1.56–2.50) < 0.000
|
1.14 (0.77–1.68) 0.520
|
|
Calcium <30d
|
|
Hormone
|
1
|
0
|
0
|
0
|
|
Non-hormone
|
10
|
10
|
10
|
10
|
|
OR (95% CI) p
|
0.56 (0.13–2.41) 0.439
|
1.58 (0.31–8.02) 0.582
|
0.49 (0.11–2.06) 0.325
|
4.14 (1.40–12.27) 0.010
|
|
Calcium ≥30d
|
|
Hormone
|
11
|
2
|
11
|
0
|
|
Non-hormone
|
37
|
37
|
37
|
37
|
|
OR (95% CI) p
|
2.15 (1.26–3.66) 0.005
|
1.88 (0.53–6.72) 0.330
|
1.99 (1.18–3.36) 0.010
|
1.64 (0.523–5.07) 0.393
|
|
Bisphosphonate <30d
|
|
Hormone
|
0
|
0
|
1
|
0
|
|
Non-hormone
|
3
|
3
|
3
|
3
|
|
OR (95% CI) p
|
0.56 (0.06–4.80) 0.592
|
- (−) 0.999
|
1.11 (0.29–4.26) 0.886
|
- (−) 0.999
|
|
Bisphosphonate ≥30d
|
|
Hormone
|
6
|
0
|
4
|
0
|
|
Non-hormone
|
12
|
12
|
12
|
12
|
|
OR (95% CI) p
|
0.93 (0.43–2.04) 0.865
|
0.84 (0.15–4.75) 0.845
|
0.69 (0.27–1.79) 0.445
|
0.75 (0.13–4.27) 0.744
|
- This table shows the number of prospective GORD positive events for hormone replacement use and non-use.
